Folgen
-
Ian describes how to leverage ChatGPT to accelerate statistical programming in the medical product industry.
Related paper available here: https://www.pharmasug.org/proceedings/2024/AP/PharmaSUG-2024-AP-256.pdf -
Elaine Hoffman, Rebbecca Wilson, Christina Nurse, and Amy LaLonde discuss the balancing act between family and career.
-
Fehlende Folgen?
-
Scott Clark, Satrajit Roychoudhury, and Michelle Shardell discuss the Statistical Partnerships Among Academe, Industry & Government (SPAIG) Committee.
https://community.amstat.org/spaig/home -
Amy welcomes Rebbecca to the co-hosting chair while Christina enjoys some time off with her new baby (congrats)! The two discuss Rebbecca’s fascinating career thus far and how communication styles differ across male and female leaders.
Reference: https://hbr.org/2022/12/research-men-speak-more-abstractly-than-women
-
Adrian and Wendy discuss imposter syndrome and being confident in your career.
-
In our first episode of the new year, we interview Steve Ruberg, an ASA fellow with over 35 years of experience in the biopharmaceutical industry and an active proponent of the Tripartite Estimand Approach.
-
Tian discusses her research in data integration methods and the bias arising from lack of representation.
-
LaShell discusses diversity, equity, and inclusion in clinical trials.
-
Elizabeth discusses imposter syndrome and how to manage it in your statistical career. In collaboration with the ASA's Committee on Career Development (CCD website) .
-
Dionne talks about her journey in biostatistics and her goals for the ASA when she becomes President in 2023.
-
This episode introduces new podcast cohosts Amy LaLonde and Christina Nurse! They take over hosting duties starting with Episode 101.
-
James Buchanan, Judy Li, Melvin Munsaka, and Bill Wang discuss the research of the Safety Scientific Working Group and their recent edited volume "Quantitative Drug Safety and Benefit Risk Evaluation: Practical and Cross-Disciplinary Approaches." https://tinyurl.com/2ucyer95
-
Devan discusses the 5-STAR methodology and endpoints for COVID vaccine clinical trials.
-
Alan is the 2022 Chair of the Biopharmaceutical Section. He discusses his wish list for things to accomplish this year.
-
Anna Nevius reflects on her time at the Center for Veterinary Medicine at the FDA and as chair of the Biopharmaceutical Section in 2009.
-
Bob Starbuck reflects on his time as chair of the Biopharmaceutical Section in 1994.
-
Amy Xia and Lanju Zhang discuss the benefits and challenges of utilizing external control arms for clinical trials.
-
Bo Huang and Gene Pennello discuss the 2021 Regulatory-Industry Statistics Workshop.
-
Joseph Cappelleri and Daniel O’Connor discuss the benefits and challenges in using patient reported outcomes and how to appropriately define clinically-meaningful change.
-
Haoda Fu, Mengling Liu, Jie Tang, Tian Zheng, and Kelly Zou discuss leadership and the impact of COVID-19 on the workplace.
- Mehr anzeigen
